Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus
- 23 August 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 12459-12467
Abstract
Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates by reverse transcription. It chronically infects >296 million people worldwide, including ∼850,000 in the USA, and kills 820,000 annually worldwide. Current nucleos(t)ide analogue (NA) or pegylated interferon α therapies do not eradicate the virus and would benefit from a complementary antiviral drug. We performed a preliminary screen of 28 dispirotripiperazines against HBV, identifying 9 hits with EC50 of 0.7-25 μM. Compound 11826096 displays the most potent activity and represents a promising lead for future optimization. While the mechanism of action is unknown, preliminary assays limit possible targets to activities involved in RNA accumulation, translation, capsid assembly, and/or capsid stability. In addition, we built machine learning models to determine if they were able to predict the activity of this series of compounds. The novelty of these molecules indicated they were outside of the applicability domain of these models.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (1R01NS102164)
- National Institute of Allergy and Infectious Diseases (R01AI122669)
- National Institute of General Medical Sciences (R44GM122196)
This publication has 45 references indexed in Scilit:
- The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase EnzymesPLOS Pathogens, 2013
- Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapyJournal of Viral Hepatitis, 2011
- Hepatitis B therapyNature Reviews Gastroenterology & Hepatology, 2011
- Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agentsJournal of Medical Virology, 2011
- Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?Journal of Gastroenterology and Hepatology, 2011
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA FormationJournal of Virology, 2007
- Inhibition of Transfer to Secondary Receptors by Heparan Sulfate-Binding Drug or Antibody Induces Noninfectious Uptake of Human PapillomavirusJournal of Virology, 2007
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004
- A cell culture assay for compounds which inhibit hepatitis B virus replicationAntiviral Research, 1991